Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERCELOI: MSCs for Osteogenesis Imperfecta
NCT02172885Phase 1Completed
- Sponsor
- Hospital Universitario de Cruces
- Start
- Apr 2014
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in osteogenesis imperfecta (OI), sponsored by Hospital Universitario de Cruces. Primary endpoint: Adverse Events as a Measure of Safety. Started Apr 2014; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT02172885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172885.